Bellevue Group’s AngioDynamics ANGO Stock Holding History

Bellevue Group’s Portfolio ANGO Stock Details ANGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-75,700	Closed	-$1.73M	–	204
2019 Q1	$1.73M	Hold	75,700	–	–	0.1%	113
2018 Q4	$1.52M	Hold	75,700	–	–	0.1%	102
2018 Q3	$1.65M	Hold	75,700	–	–	0.1%	109
2018 Q2	$1.68M	Sell	75,700 -26,000	-26%	-$531K	0.14%	96
2018 Q1	$1.75M	Hold	101,700	–	–	0.17%	85
2017 Q4	$1.69M	Hold	101,700	–	–	0.18%	88
2017 Q3	$1.74M	Hold	101,700	–	–	0.18%	87
2017 Q2	$1.65M	Hold	101,700	–	–	0.2%	88
2017 Q1	$1.76M	Hold	101,700	–	–	0.24%	82
2016 Q4	$1.72M	Sell	101,700 -28,300	-22%	-$472K	0.35%	69
2016 Q3	$2.28M	Sell	130,000 -21,400	-14%	-$347K	0.41%	69
2016 Q2	$2.18M	Hold	151,400	–	–	0.41%	70
2016 Q1	$1.86M	Buy	+151,400	New	+$1.67M	0.34%	80

Other funds holding ANGO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TCM

Tributary Capital Management Omaha, Nebraska $1.03B AUM 19.64% 1-Year Est. Return

Bellevue Group's ANGO Position: Q2 2019 in Review

Bellevue Group sold out of AngioDynamics (ANGO) in Q2 2019, closing a stake of 75,700 shares — an estimated $1.73M sold.

Bellevue Group first reported a position in ANGO in Q1 2016 and held it in 13 quarters. The position peaked at $2.28M in Q3 2016. 167 funds tracked by Wall St. Rank hold ANGO as of Q2 2019.

Bellevue Group reported no remaining AngioDynamics position as of Q2 2019 after selling out during the quarter.
Bellevue Group sold 75,700 AngioDynamics shares in Q2 2019, an estimated $1.73M.
Bellevue Group first reported a position in AngioDynamics in Q1 2016 and held it in 13 quarters.
Bellevue Group's AngioDynamics position peaked at $2.28M in Q3 2016.
167 funds tracked by Wall St. Rank held AngioDynamics as of Q2 2019.

Based on Bellevue Group's 13F filing for Q2 2019, filed 14 Aug 2019.